公开(公告)号：US20110009472A1

公开(公告)日：2011-01-13

申请号：US12845521

申请日：2010-07-28

申请人： Martin Gleave ,  Burkhard Jansen ,  Ioannis P. Trougakos ,  Efstathios Gonos ,  Maxim Signaevsky ,  Eliana Beraldi

发明人： Martin Gleave ,  Burkhard Jansen ,  Ioannis P. Trougakos ,  Efstathios Gonos ,  Maxim Signaevsky ,  Eliana Beraldi

IPC分类号： A61K31/7088 ,  A61P35/00 ,  A61K31/713

CPC分类号： C12N15/113 ,  A61K31/712 ,  A61K38/00 ,  C12N2310/315 ,  C12N2310/321 ,  C12N2310/341 ,  C12N2310/346 ,  C12N2310/3525

摘要： RNAi sequences that are useful as therapeutics in the treatment of cancers of various types, including prostate cancer, sarcomas such as osteosarcoma, renal cell carcinoma, breast cancer, bladder cancer, lung cancer, colon cancer, ovarian cancer, anaplastic large cell lymphoma and melanoma; and Alzheimer's disease. These sequences target clusterin, IGFBP-5, IGFBP-2, both IGFBP-2 and -5 simultaneously, Mitf, and B-raf. The invention further provides for the use of these RNAi sequences in the treatment of cancers of various types, including prostate cancer, sarcomas such as osteosarcoma, renal cell carcinoma, breast cancer, bladder cancer, lung cancer, colon cancer, ovarian cancer, anaplastic large cell lymphoma and melanoma; and Alzheimer's disease, and a method of treating such conditions through the administration of the RNA molecules with RNAi activity to an individual, including a human individual in need of such treatment.

摘要翻译： 可用作治疗各种类型癌症的RNAi序列，包括前列腺癌，肉瘤如骨肉瘤，肾细胞癌，乳腺癌，膀胱癌，肺癌，结肠癌，卵巢癌，间变性大细胞淋巴瘤和黑素瘤 ; 和阿尔茨海默病。 这些序列同时靶向簇蛋白，IGFBP-5，IGFBP-2，IGFBP-2和-5两者，Mitf和B-raf。 本发明进一步提供这些RNAi序列用于治疗各种类型的癌症，包括前列腺癌，肉瘤如骨肉瘤，肾细胞癌，乳腺癌，膀胱癌，肺癌，结肠癌，卵巢癌，间变性大 细胞淋巴瘤和黑素瘤; 和阿尔茨海默病，以及通过向包括需要这种治疗的人的个体的个体施用具有RNAi活性的RNA分子来治疗这些病症的方法。

公开(公告)号：US20080274996A1

公开(公告)日：2008-11-06

申请号：US12116083

申请日：2008-05-06

申请人： Martin Gleave ,  Burkhard Jansen ,  Ioannis P. Trougakos ,  Efstathios Gonos ,  Maxim Signaevsky ,  Eliana Beraldi

发明人： Martin Gleave ,  Burkhard Jansen ,  Ioannis P. Trougakos ,  Efstathios Gonos ,  Maxim Signaevsky ,  Eliana Beraldi

IPC分类号： A61K31/7105 ,  C07H21/02 ,  A61P35/00

CPC分类号： C12N15/113 ,  A61K31/712 ,  A61K38/00 ,  C12N2310/315 ,  C12N2310/321 ,  C12N2310/341 ,  C12N2310/346 ,  C12N2310/3525

摘要： RNAi sequences that are useful as therapeutics in the treatment of cancers of various types, including prostate cancer, sarcomas such as osteosarcoma, renal cell carcinoma, breast cancer, bladder cancer, lung cancer, colon cancer, ovarian cancer, anaplastic large cell lymphoma and melanoma; and Alzheimer's disease. These sequences target clusterin, IGFBP-5, IGFBP-2, both IGFBP-2 and -5 simultaneously, Mitf, and B-raf. The invention further provides for the use of these RNAi sequences in the treatment of cancers of various types, including prostate cancer, sarcomas such as osteosarcoma, renal cell carcinoma, breast cancer, bladder cancer, lung cancer, colon cancer, ovarian cancer, anaplastic large cell lymphoma and melanoma; and Alzheimer's disease, and a method of treating such conditions through the administration of the RNA molecules with RNAi activity to an individual, including a human individual in need of such treatment.

摘要翻译： 可用作治疗各种类型癌症的RNAi序列，包括前列腺癌，肉瘤如骨肉瘤，肾细胞癌，乳腺癌，膀胱癌，肺癌，结肠癌，卵巢癌，间变性大细胞淋巴瘤和黑素瘤 ; 和阿尔茨海默病。 这些序列同时靶向簇蛋白，IGFBP-5，IGFBP-2，IGFBP-2和-5两者，Mitf和B-raf。 本发明进一步提供这些RNAi序列用于治疗各种类型的癌症，包括前列腺癌，肉瘤如骨肉瘤，肾细胞癌，乳腺癌，膀胱癌，肺癌，结肠癌，卵巢癌，间变性大 细胞淋巴瘤和黑素瘤; 和阿尔茨海默病，以及通过向包括需要这种治疗的人的个体的个体施用具有RNAi活性的RNA分子来治疗这些病症的方法。

公开(公告)号：US09487777B2

公开(公告)日：2016-11-08

申请号：US13404741

申请日：2012-02-24

申请人： Martin Gleave ,  Burkhard Jansen ,  Ioannis P. Trougakos ,  Efstathios Gonos ,  Maxim Signaevsky ,  Eliana Beraldi

发明人： Martin Gleave ,  Burkhard Jansen ,  Ioannis P. Trougakos ,  Efstathios Gonos ,  Maxim Signaevsky ,  Eliana Beraldi

IPC分类号： C07H21/04 ,  C12N15/113 ,  A61K31/712 ,  A61K38/00

CPC分类号： C12N15/113 ,  A61K31/712 ,  A61K38/00 ,  C12N2310/315 ,  C12N2310/321 ,  C12N2310/341 ,  C12N2310/346 ,  C12N2310/3525

摘要： RNAi sequences that are useful as therapeutics in the treatment of cancers of various types, including prostate cancer, sarcomas such as osteosarcoma, renal cell carcinoma, breast cancer, bladder cancer, lung cancer, colon cancer, ovarian cancer, anaplastic large cell lymphoma and melanoma; and Alzheimer's disease. These sequences target clusterin, IGFBP-5, IGFBP-2, both IGFBP-2 and -5 simultaneously, Mitf, and B-raf. The invention further provides for the use of these RNAi sequences in the treatment of cancers of various types, including prostate cancer, sarcomas such as osteosarcoma, renal cell carcinoma, breast cancer, bladder cancer, lung cancer, colon cancer, ovarian cancer, anaplastic large cell lymphoma and melanoma; and Alzheimer's disease, and a method of treating such conditions through the administration of the RNA molecules with RNAi activity to an individual, including a human individual in need of such treatment.

摘要翻译： 可用作治疗各种类型癌症的RNAi序列，包括前列腺癌，肉瘤如骨肉瘤，肾细胞癌，乳腺癌，膀胱癌，肺癌，结肠癌，卵巢癌，间变性大细胞淋巴瘤和黑素瘤 ; 和阿尔茨海默病。 这些序列同时靶向簇蛋白，IGFBP-5，IGFBP-2，IGFBP-2和-5两者，Mitf和B-raf。 本发明进一步提供这些RNAi序列用于治疗各种类型的癌症，包括前列腺癌，肉瘤如骨肉瘤，肾细胞癌，乳腺癌，膀胱癌，肺癌，结肠癌，卵巢癌，间变性大 细胞淋巴瘤和黑素瘤; 和阿尔茨海默病，以及通过向包括需要这种治疗的人的个体的个体施用具有RNAi活性的RNA分子来治疗这些病症的方法。

公开(公告)号：US08759308B2

公开(公告)日：2014-06-24

申请号：US12845521

申请日：2010-07-28

申请人： Martin Gleave ,  Burkhard Jansen ,  Ioannis P Trougakos ,  Efstathios Gonos ,  Maxim Signaevsky ,  Eliana Beraldi

发明人： Martin Gleave ,  Burkhard Jansen ,  Ioannis P Trougakos ,  Efstathios Gonos ,  Maxim Signaevsky ,  Eliana Beraldi

IPC分类号： A61K48/00

CPC分类号： C12N15/113 ,  A61K31/712 ,  A61K38/00 ,  C12N2310/315 ,  C12N2310/321 ,  C12N2310/341 ,  C12N2310/346 ,  C12N2310/3525

摘要： RNAi sequences that are useful as therapeutics in the treatment of cancers of various types, including prostate cancer, sarcomas such as osteosarcoma, renal cell carcinoma, breast cancer, bladder cancer, lung cancer, colon cancer, ovarian cancer, anaplastic large cell lymphoma and melanoma; and Alzheimer's disease. These sequences target clusterin, IGFBP-5, IGFBP-2, both IGFBP-2 and -5 simultaneously, Mitf, and B-raf. The invention further provides for the use of these RNAi sequences in the treatment of cancers of various types, including prostate cancer, sarcomas such as osteosarcoma, renal cell carcinoma, breast cancer, bladder cancer, lung cancer, colon cancer, ovarian cancer, anaplastic large cell lymphoma and melanoma; and Alzheimer's disease, and a method of treating such conditions through the administration of the RNA molecules with RNAi activity to an individual, including a human individual in need of such treatment.

摘要翻译： 可用作治疗各种类型癌症的RNAi序列，包括前列腺癌，肉瘤如骨肉瘤，肾细胞癌，乳腺癌，膀胱癌，肺癌，结肠癌，卵巢癌，间变性大细胞淋巴瘤和黑素瘤 ; 和阿尔茨海默病。 这些序列同时靶向簇蛋白，IGFBP-5，IGFBP-2，IGFBP-2和-5两者，Mitf和B-raf。 本发明进一步提供这些RNAi序列用于治疗各种类型的癌症，包括前列腺癌，肉瘤如骨肉瘤，肾细胞癌，乳腺癌，膀胱癌，肺癌，结肠癌，卵巢癌，间变性大 细胞淋巴瘤和黑素瘤; 和阿尔茨海默病，以及通过向包括需要这种治疗的人的个体的个体施用具有RNAi活性的RNA分子来治疗这些病症的方法。

公开(公告)号：US20120202873A1

公开(公告)日：2012-08-09

申请号：US13404741

申请日：2012-02-24

申请人： Martin Gleave ,  Burkhard Jansen ,  Ioannis P. Trougakos ,  Efstathios Gonos ,  Maxim Signaevsky ,  Eliana Beraldi

发明人： Martin Gleave ,  Burkhard Jansen ,  Ioannis P. Trougakos ,  Efstathios Gonos ,  Maxim Signaevsky ,  Eliana Beraldi

IPC分类号： C07H21/02 ,  A61P35/04 ,  A61K31/7105

CPC分类号： C12N15/113 ,  A61K31/712 ,  A61K38/00 ,  C12N2310/315 ,  C12N2310/321 ,  C12N2310/341 ,  C12N2310/346 ,  C12N2310/3525

摘要： RNAi sequences that are useful as therapeutics in the treatment of cancers of various types, including prostate cancer, sarcomas such as osteosarcoma, renal cell carcinoma, breast cancer, bladder cancer, lung cancer, colon cancer, ovarian cancer, anaplastic large cell lymphoma and melanoma; and Alzheimer's disease. These sequences target clusterin, IGFBP-5, IGFBP-2, both IGFBP-2 and -5 simultaneously, Mitf, and B-raf. The invention further provides for the use of these RNAi sequences in the treatment of cancers of various types, including prostate cancer, sarcomas such as osteosarcoma, renal cell carcinoma, breast cancer, bladder cancer, lung cancer, colon cancer, ovarian cancer, anaplastic large cell lymphoma and melanoma; and Alzheimer's disease, and a method of treating such conditions through the administration of the RNA molecules with RNAi activity to an individual, including a human individual in need of such treatment.

摘要翻译： 可用作治疗各种类型癌症的RNAi序列，包括前列腺癌，肉瘤如骨肉瘤，肾细胞癌，乳腺癌，膀胱癌，肺癌，结肠癌，卵巢癌，间变性大细胞淋巴瘤和黑素瘤 ; 和阿尔茨海默病。 这些序列同时靶向簇蛋白，IGFBP-5，IGFBP-2，IGFBP-2和-5两者，Mitf和B-raf。 本发明进一步提供这些RNAi序列用于治疗各种类型的癌症，包括前列腺癌，肉瘤如骨肉瘤，肾细胞癌，乳腺癌，膀胱癌，肺癌，结肠癌，卵巢癌，间变性大 细胞淋巴瘤和黑素瘤; 和阿尔茨海默病，以及通过向包括需要这种治疗的人的个体的个体施用具有RNAi活性的RNA分子来治疗这些病症的方法。

公开(公告)号：US07820635B2

公开(公告)日：2010-10-26

申请号：US12116083

申请日：2008-05-06

申请人： Martin Gleave ,  Burkhard Jansen ,  Ioannis P Trougakos ,  Efstathios Gonos ,  Maxim Signaevsky ,  Eliana Beraldi

发明人： Martin Gleave ,  Burkhard Jansen ,  Ioannis P Trougakos ,  Efstathios Gonos ,  Maxim Signaevsky ,  Eliana Beraldi

IPC分类号： A61K48/00

CPC分类号： C12N15/113 ,  A61K31/712 ,  A61K38/00 ,  C12N2310/315 ,  C12N2310/321 ,  C12N2310/341 ,  C12N2310/346 ,  C12N2310/3525

摘要： RNAi sequences that are useful as therapeutics in the treatment of cancers of various types, including prostate cancer, sarcomas such as osteosarcoma, renal cell carcinoma, breast cancer, bladder cancer, lung cancer, colon cancer, ovarian cancer, anaplastic large cell lymphoma and melanoma; and Alzheimer's disease. These sequences target clusterin, IGFBP-5, IGFBP-2, both IGFBP-2 and -5 simultaneously, Mitf, and B-raf. The invention further provides for the use of these RNAi sequences in the treatment of cancers of various types, including prostate cancer, sarcomas such as osteosarcoma, renal cell carcinoma, breast cancer, bladder cancer, lung cancer, colon cancer, ovarian cancer, anaplastic large cell lymphoma and melanoma; and Alzheimer's disease, and a method of treating such conditions through the administration of the RNA molecules with RNAi activity to an individual, including a human individual in need of such treatment.

摘要翻译： 可用作治疗各种类型癌症的RNAi序列，包括前列腺癌，肉瘤如骨肉瘤，肾细胞癌，乳腺癌，膀胱癌，肺癌，结肠癌，卵巢癌，间变性大细胞淋巴瘤和黑素瘤 ; 和阿尔茨海默病。 这些序列同时靶向簇蛋白，IGFBP-5，IGFBP-2，IGFBP-2和-5两者，Mitf和B-raf。 本发明进一步提供这些RNAi序列用于治疗各种类型的癌症，包括前列腺癌，肉瘤如骨肉瘤，肾细胞癌，乳腺癌，膀胱癌，肺癌，结肠癌，卵巢癌，间变性大 细胞淋巴瘤和黑素瘤; 和阿尔茨海默病，以及通过向包括需要这种治疗的人的个体的个体施用具有RNAi活性的RNA分子来治疗这些病症的方法。

公开(公告)号：US20060178329A1

公开(公告)日：2006-08-10

申请号：US11276300

申请日：2006-02-23

申请人： Martin Gleave ,  Burkhard Jansen ,  Ioannis Trougakos ,  Efstathios Gonos ,  Maxim Signaevsky ,  Eliana Beraldi

发明人： Martin Gleave ,  Burkhard Jansen ,  Ioannis Trougakos ,  Efstathios Gonos ,  Maxim Signaevsky ,  Eliana Beraldi

IPC分类号： A61K48/00 ,  C07H21/02

CPC分类号： C12N15/113 ,  A61K31/712 ,  A61K38/00 ,  C12N2310/315 ,  C12N2310/321 ,  C12N2310/341 ,  C12N2310/346 ,  C12N2310/3525

摘要： RNAi sequences that are useful as therapeutics in the treatment of cancers of various types, including prostate cancer, sarcomas such as osteosarcoma, renal cell carcinoma, breast cancer, bladder cancer, lung cancer, colon cancer, ovarian cancer, anaplastic large cell lymphoma and melanoma; and Alzheimer's disease. These sequences target clusterin, IGFBP-5, IGFBP-2, both IGFBP-2 and -5 simultaneously, Mitf, and B-raf. The invention farther provides for the use of these RNAi sequences in the treatment of cancers of various types, including prostate cancer, sarcomas such as osteosarcoma, renal cell carcinoma, breast cancer, bladder cancer, lung cancer, colon cancer, ovarian cancer, anaplastic large cell lymphoma and melanoma; and Alzheimer's disease, and a method of treating such conditions through the administration of the RNA molecules with RNAi activity to an individual, including a human individual in need of such treatment.

摘要翻译： 可用作治疗各种类型癌症的RNAi序列，包括前列腺癌，肉瘤如骨肉瘤，肾细胞癌，乳腺癌，膀胱癌，肺癌，结肠癌，卵巢癌，间变性大细胞淋巴瘤和黑素瘤 ; 和阿尔茨海默病。 这些序列同时靶向簇蛋白，IGFBP-5，IGFBP-2，IGFBP-2和-5两者，Mitf和B-raf。 本发明进一步提供这些RNAi序列用于治疗各种类型的癌症，包括前列腺癌，肉瘤如骨肉瘤，肾细胞癌，乳腺癌，膀胱癌，肺癌，结肠癌，卵巢癌，间变性大 细胞淋巴瘤和黑素瘤; 和阿尔茨海默病，以及通过向包括需要这种治疗的人的个体的个体施用具有RNAi活性的RNA分子来治疗这些病症的方法。

公开(公告)号：US20060276424A1

公开(公告)日：2006-12-07

申请号：US11422481

申请日：2006-06-06

申请人： Martin Gleave ,  Palma Rocchi ,  Maxim Signaevsky ,  Eliana Beraldi

发明人： Martin Gleave ,  Palma Rocchi ,  Maxim Signaevsky ,  Eliana Beraldi

IPC分类号： A61K48/00

CPC分类号： C12N15/113 ,  A61K31/337 ,  A61K31/7068 ,  A61K31/7088 ,  A61K31/7125 ,  A61K31/713 ,  A61K48/005 ,  C12N2310/11 ,  C12N2310/14 ,  C12N2310/315 ,  C12N2320/30 ,  C12N2320/31

摘要： Therapeutic agents which target heat shock protein (hsp) 27 in vivo are used to provide treatment to individuals, particularly human individuals, suffering from prostate cancer and other cancers that overexpress hsp27. A therapeutic agent, for example an antisense oligonucleotide or RNAi nucleotide inhibitor with sequence specificity for hsp27 mRNA, for example human hsp27 mRNA, is administered to an individual suffering from prostate cancer or some other cancer expressing elevated levels of hsp 27 in a therapeutically effective amount. The therapeutic agent is suitably formulated into a pharmaceutical composition which includes a pharmaceutically acceptable carrier, and packaged in dosage unit form. A preferred dosage unit form is an injectable dosage unit form.

公开(公告)号：US20060040886A1

公开(公告)日：2006-02-23

申请号：US11262388

申请日：2005-10-28

申请人： Martin Gleave ,  Palma Rocchi ,  Maxim Signaevsky ,  Eliana Beraldi

发明人： Martin Gleave ,  Palma Rocchi ,  Maxim Signaevsky ,  Eliana Beraldi

IPC分类号： A61K48/00

CPC分类号： C12N15/113 ,  A61K31/337 ,  A61K31/7068 ,  A61K31/7088 ,  A61K31/7125 ,  A61K31/713 ,  A61K48/005 ,  C12N2310/11 ,  C12N2310/14 ,  C12N2310/315 ,  C12N2320/30 ,  C12N2320/31

摘要： Therapeutic agents which target heat shock protein (hsp) 27 in vivo are used to provide treatment to individuals, particularly human individuals, suffering from prostate cancer and other cancers that overexpress hsp27. A therapeutic agent, for example an antisense oligonucleotide or RNAi nucleotide inhibitor with sequence specificity for hsp27 mRNA, for example human hsp27 mRNA, is administered to an individual suffering from prostate cancer or some other cancer expressing elevated levels of hsp 27 in a therapeutically effective amount. The therapeutic agent is suitably formulated into a pharmaceutical composition which includes a pharmaceutically acceptable carrier, and packaged in dosage unit form. A preferred dosage unit form is an injectable dosage unit form.

公开(公告)号：US08772470B1

公开(公告)日：2014-07-08

申请号：US11948195

申请日：2007-11-30

申请人： Martin Gleave ,  Palma Rocchi ,  Maxim Signaevsky ,  Eliana Beraldi

发明人： Martin Gleave ,  Palma Rocchi ,  Maxim Signaevsky ,  Eliana Beraldi

IPC分类号： C07H21/04 ,  C07H21/02 ,  A61K48/00

CPC分类号： C12N15/113 ,  A61K31/337 ,  A61K31/7068 ,  A61K31/7088 ,  A61K31/7125 ,  A61K31/713 ,  A61K48/005 ,  C12N2310/11 ,  C12N2310/14 ,  C12N2310/315 ,  C12N2320/30 ,  C12N2320/31

摘要： Therapeutic agents which target heat shock protein (hsp) 27 in vivo are used to provide treatment to individuals, particularly human individuals, suffering from prostate cancer and other cancers that overexpress hsp27. A therapeutic agent, for example an antisense oligonucleotide or RNAi nucleotide inhibitor with sequence specificity for hsp27 mRNA, for example human hsp27 mRNA, is administered to an individual suffering from prostate cancer or some other cancer expressing elevated levels of hsp 27 in a therapeutically effective amount. The therapeutic agent is suitably formulated into a pharmaceutical composition which includes a pharmaceutically acceptable carrier, and packaged in dosage unit form. A preferred dosage unit form is an injectable dosage unit form.

摘要翻译： 靶向体内热休克蛋白（hsp）27的治疗剂用于为患有前列腺癌和过表达hsp27的其他癌症的个体，特别是人类个体提供治疗。 将治疗剂，例如具有hsp27mRNA的序列特异性的反义寡核苷酸或RNAi核苷酸抑制剂（例如人hsp27 mRNA）施用于患有前列腺癌或表达治疗有效量的高水平hsp27的一些其它癌症的个体 。 治疗剂适当地配制成包含药学上可接受的载体并以剂量单位形式包装的药物组合物。 优选的剂量单位形式是可注射剂量单位形式。